Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Warrants Expiration Dates per Q2 M&D
View:
Post by 99942Apophis on Sep 22, 2022 8:33am

Warrants Expiration Dates per Q2 M&D

As of August 29, 2022, there were 64,759,165 warrants outstanding. Each whole warrant entitles the holder thereof to purchase one additional common share.
The warrants are exercisable as follows: 3,165,008 at a price of $0.50 until October 3, 2022, 4,095,157 at a price of $0.50 until January 9, 2023, and 57,499,000 at a price of $0.35 until August 22, 2024.
Comment by 99942Apophis on Sep 22, 2022 9:43am
99942Apophis wrote  As of August 29, 2022, there were 64,759,165 warrants outstanding. Each whole warrant entitles the holder thereof to purchase one additional common share. The warrants are exercisable as follows: 3,165,008 at a price of $0.50 until October 3, 2022, 4,095,157 at a price of $0.50 until January 9, 2023, and 57,499,000 at a price of $0.35 until August 22, 2024. Chances are ...more  
Comment by ScienceFirst on Sep 22, 2022 11:02pm
So 3.5M$ (1.55M$ + 2.05M$) more from the next 2 sets of warrants, if good news brings this stock higher than 0.50$.  Otherwise, this will erase 7.25M shares. The current pp (of today) adds up to 17M shares (10M shares + 7.1M shares from warrants @0.35$). So both ways, this is a very small pp, in regards to what could happen with the next 2 sets of warrants. Now, that would be fun to see ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250